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The human cardiac sodium channel Nav1.5 encoded by the SCN5A gene plays a critical role
in cardiac excitability and the propagation of action potentials. Nav1.5 dysfunctions due to
mutations cause cardiac diseases such as the LQT3 form of long QT syndrome, conduc-
tion disorders, and Brugada syndrome (BrS).They have also recently been associated with
dilated cardiomyopathy. BrS is characterized by coved ST-segment elevation on surface
ECGs and lethal ventricular arrhythmias in an apparently structurally normal heart. Nav1.5
mutations that cause BrS result in a loss of channel function. Our aim was to functionally
characterize two novel Nav1.5 mutations (A124D and V1378M) in BrS patients. Wild-type
(WT) andmutant Nav1.5 channels were expressed in tsA201 cells in the presence of the β1-
auxiliary subunit. The patch-clamp technique and immunocytochemistry approaches were
used to study the mutant channels and their cellular localization. The two mutant chan-
nels displayed a dramatic reduction in current density but had normal gating properties.
The reduction in current density was caused by the retention of channel proteins in the
endoplasmic reticulum (ER). Mutant channel retention could be partially reversed by incu-
bating transfected cells at 25˚C and by treating them with mexiletine (for V1378M but not
A124D), or with curcumin or thapsigargin, two drugs that target ER resident proteins. It
is likely that the clinical phenotypes observed in these two BrS patients were related to a
surface expression defect caused by ER retention.
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INTRODUCTION
The cardiac Nav1.5 channel encoded by the SCN5A gene plays a
critical role in cardiac excitability and conduction. It is responsi-
ble for the rapid upstroke of the action potential (AP) caused by
the rapid entry of Na+ ions into cardiac myocytes. Dysfunctions
of this channel cause diseases such as type 3 long QT syndrome
(LQT), Brugada syndrome (BrS), and conduction disorders. More
recently, SCN5A mutations have been associated with dilated car-
diomyopathy (Amin et al., 2010). BrS is characterized by a coved-
type ST-segment elevation inV1 throughV3derivations on surface
ECGs and a right bundle branch block pattern in a morpholog-
ically normal heart. This pathology leads to high mortality due
to malignant ventricular arrhythmias (Bhar-Amato et al., 2010).
Coved-type ST-segment elevations are characteristic of BrS type 1
ECGs, whereas saddle-back ST-segment elevations correspond to
BrS type 2 and 3 ECGs (Wilde et al., 2002). Type 1 BrS ECGs can
be unmasked by potent Na+ channel blockers and other factors
such as fever (Keller et al., 2006).
BrS is an inherited arrhythmic syndrome related to mutations
in the SCN5A gene in 10–30% of cases (Antzelevitch, 2006; Zim-
mer and Surber, 2008). Others genes such as SNC1B and GDP1L
as well as genes that code for calcium channel subunits are also
linked to this syndrome (Antzelevitch, 2006; London et al., 2007;
Watanabe et al., 2008; Zimmer and Surber, 2008).
A number of SCN5A mutations that lead to BrS cause traf-
ﬁcking defects (Baroudi et al., 2001; Valdivia et al., 2004). Various
treatments can correct these defects in vivo, including incubating
transfected cells at low temperature (25˚C)or treating the cellswith
mexiletine (class I antiarrhythmic), or curcumin and thapsigargin,
two drugs that act on the SERCA pump in the endoplasmic retic-
ulum (ER) membrane (Baroudi et al., 2002; Valdivia et al., 2004;
Keller et al., 2005). All these treatments target various aspect of
the retention mechanism of channels such as heat shock proteins
(HSP) and calnexin, a reticular chaperone (Zhou et al., 1999; Egan
et al., 2004).
We studied the biophysical properties and cellular localiza-
tion of two mutations in BrS patients. Two highly conserved
residues, alanine 124 and valine 1378, were substituted by an
aspartic acid and a methionine, respectively. We investigated how
these two mutations, which are located in different regions on
the channel, caused a loss of function. We observed a dramatic
reduction in Na+ currents following the transient expression of
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mutant Nav1.5 channels in tsA201 cells. A reduction in the incu-
bation temperature and a number of chemical treatments partially
restored the Na+ currents, suggesting that the mutations caused
ER retention.
MATERIALS AND METHODS
CLINICAL EVALUATIONS AND MOLECULAR GENETICS
Written informed consentwas obtained from the twoparticipating
index patients in accordance with the study protocol, which was
approved by the ethics committee of the University Hospital of
Basel, Switzerland. The investigation conformed to the principles
set out in the Declaration of Helsinki. Index patients underwent
detailed clinical assessments, including 12-lead ECGs and speciﬁc
examinations related to the clinical presentation of BrS.
Genomic DNA was extracted from peripheral lymphocytes
isolated from the two patients. The coding exons of SCN5A
were ampliﬁed by PCR using primers designed with intronic
ﬂanking sequences according to the gene sequence described
by Wang et al. (1996). Denaturating high performance liquid
chromatography (dHPLC) was performed on DNA ampliﬁca-
tion products using at least one temperature condition. Abnormal
dHPLC proﬁles were analyzed by cycle sequencing both strands
of the exons using a big dye termination mix and an auto-
mated laser ﬂuorescent DNA sequencer (ABI Prism 377, Applied
Biosystems, Foster City, CA, USA). No mutations on SCN5A
gene were found in the chromosomes of 200 normal control
subjects.
CELL CULTURES
The tsA201 cell line is a modiﬁed human embryonic kidney HEK-
293 cell line stably transfected by the simian virus 40 large T anti-
gen that can promote the replication of viral promoter-containing
constructs (Huang et al., 2011). The cells were transfected with
WT or mutant human Nav1.5 cDNA (2–5μg) and the human
β1-subunit (2–5μg) using the calcium-phosphate method as pre-
viously described (Deschenes et al., 2000) and were grown at 37˚C
in a 5%CO2 humidiﬁed atmosphere in high-glucose DMEM sup-
plementedwith 10% fetal bovine serum (FBS), 2mM l-glutamine,
100U/ml of penicillin G, and 10mg/ml of streptomycin (GIBCO-
BRLLife Technologies,Burlington,ON,Canada). The humanNa+
channelβ1-subunit andCD8were inserted in thepIRESbicistronic
vector in the form of pCD8-IRES-β1. For the patch-clamp experi-
ments, the cells were incubated for 2min in an extracellular solu-
tion containing anti-CD8-coated beads 2 days after transfection
(Dynabeads CD8, Dynal Biotech, Oslo, Norway).
PATCH-CLAMP ELECTROPHYSIOLOGY
Macroscopic Na+ currents from transfected cells were recorded
using the whole-cell conﬁguration of the patch-clamp technique
as previously described (Huang et al., 2011).
SOLUTIONS AND REAGENTS
The patch pipettes were ﬁlled with a solution containing 35mM
NaCl, 105mMCsF, 10mMEGTA, and 10mMCs-HEPES. The pH
was adjusted to 7.4 using 1N CsOH. The bath solution contained
150mM NaCl, 2mM KCl, 1.5mM CaCl2, 1mM MgCl2, 10mM
glucose, and 10mM Na–HEPES. The pH was adjusted to pH 7.4
using 1N NaOH. The liquid junction potential between the patch
pipette and the bath solution was corrected by −7mV. Mexile-
tine, curcumin, and thapsigargin (Sigma) were used at 400μM
(overnight incubation), 25μM (4-h incubation), and 1μM (2-h
incubation), respectively. Curcumin and thapsigarginwere diluted
in DMSO. Consequently, when indicated cells were incubated in
0.25% of DMSO.
IMMUNOCYTOCHEMISTRY
Transfected tsA201 cells were ﬁxed in a PBS/4% paraformalde-
hyde/4% sucrose solution for 20min and were then permeabilized
using 0.1% Triton in PBS/1% BSA. They were then incubated
with rabbit anti-FLAG Ab-1 primary antibody (1:1000) to detect
FLAG-tagged Nav1.5 channels (Fisher Scientiﬁc). The tag epitope
was inserted in the S5 to S6 extracellular loop of domain I in
the WT and mutant channels. A mouse anti-calnexin antibody
(1:200, StressGen Biotechnologies Corp., Victoria, BC, Canada)
was used to label the ER. The permeabilized cells were then
incubated with F(ab′)2-conjugated goat anti-rabbit (1:250) and
F(ab′)2-conjugated goat anti-mouse (1:250) secondary antibodies
(Invitrogen). The cells were also incubated with DAPI (5μg/ml)
to label the nucleus. The cells were examined using a confocal
Zeiss LSM 510 microscope equipped with a 63× oil immersion
objective with a 1.4 numerical aperture and the appropriate lasers.
STATISTICAL ANALYSIS
Data are expressed as means± SEMs. When indicated, a t -test
or one-way ANOVA was performed using software in SigmaPlot
(Jandel Scientiﬁc Software). Differences were considered statisti-
cally signiﬁcant at p< 0.05 (∗/#), p< 0.01 (∗∗/##), and p< 0.001
(∗∗∗/###).
RESULTS
CLINICAL PHENOTYPES OF BRUGADA SYNDROME
Patient 1
A 32-year-old male patient was admitted to the emergency care
unit due to syncope during walking with spontaneous recovery. At
the time, the patient suffered from a febrile infection with gastric
symptoms. The 12-lead ECG with a BrS type 1 pattern at admis-
sion with a fever (39˚C) is shown in the upper panel of Figure 1A.
The administration of an antipyretic changed the BrS type 1 ECG
to a BrS type 3 ECGpattern (Figure 1A, lower panel). The patient’s
history revealed that he had had long-standing, multiple, neurally
mediated, vasovagal syncopes in the past. To differentiate the syn-
cope from one of neurally mediated origin, we performed a head
up tilt table test (Figure 1C), which was mixed positive after 3min
at a tilt angle of 60˚ (a syncope with a drop in blood pressure to
75/49mmHg and a 13-s asystole that disappeared spontaneously
when the patient was returned to the supine position (Moya et al.,
2009). No ventricular arrhythmias were observed during tilt table
test or recovery phase. No implantable cardioverter-deﬁbrillator
(ICD) was implanted. Follow-up to date has been uneventful.
There was no family history of sudden cardiac death (SCD), but
the patient’s mother and brother had also suffered from vasovagal
syncopes. Their ECGs were normal, but had never been recorded
while they had a fever or after a ﬂecainide challenge. They refused
genotyping.
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FIGURE 1 | ECG, tilt table, and genotype: Patient 1. (A) Upper panel:
12-lead ECG while febrile (39˚C) showing a BrS type 1 ECG with coved
ST-segment elevation in the right precordial leads; lower panel: 12-lead
ECG while afebrile showing a BrS type 3 ECG with saddle-back
ST-segment elevation in the right precordial leads. (B) c.371 C>A resulted
in a heterozygous p.A124D mutation in SCN5A. (C) Asystole during tilt
table testing, with spontaneous recovery of the sinus rhythm in the supine
position.
Patient 2
A 60-year-old male patient was admitted to the hospital due to a
ﬁrst episode of violent syncope with a basilar skull fracture and
subarachnoid hemorrhage. The transthoracic echocardiography
was normal, and left heart catheterization revealed normal coro-
nary arteries. A 12-lead ECG showed a typical BrS type 1 pattern
with coved ST-segment elevation (Figure 2A). The patient had no
fever during the syncope or ECG recording. The family history
revealed that a paternal uncle had unexpectedly died at the age of
64. An ICD was implanted in the patient. Follow-up to date has
been uneventful. Further family screeningwas not performed. The
patient has no children.
IDENTIFICATION OF THE p.A124D AND p.V1378M MUTATIONS IN SCN5A
We identiﬁed two novel missense mutation (p.A124D and
p.V1378M) in the SCN5A genes of the two index patients
(Figures 1B and 2B). Patient 1 had a heterozygous C to A base
change at position 371 in exon 3 of SCN5A that resulted in the
substitution of an alanine (GCT) for an asparagine (GAT) in
residue 124 (Figure 1B). The mutation was located in the C-
terminal region of the Nav1.5 channel (Figure 3). Patient 2 had a
heterozygous G to A base change at position 4132 in exon 23 that
resulted in the substitution of a valine (GTG) for a methionine
(ATG) in residue 1378 (Figure 2B). The mutation was located in
the third domain between the ﬁfth and sixth transmembrane seg-
ment of the Nav1.5 channel (Figure 3). Both mutations affected
residues that are highly conserved inNa+ channels inmany species
(data not shown).
BIOPHYSICAL PROPERTIES OF THE A124D AND V1378M MUTANTS
To understand the clinical phenotypes of the two patients, the
biophysical properties of the WT and mutant channels were
studied. Macroscopic Na+ currents were recorded from trans-
fected tsA201 cells. A dramatic reduction in current amplitudes
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was observed with both mutants. Examples of whole-cell cur-
rent traces (A) and I–V relationship curves (B) are shown in
Figure 4. The non-signiﬁcant variation of the reversal potentials of
WT (29.9± 1.2mV, n = 10), A124D (35.6± 2.4mV, n = 14), and
V1378M (30.4± 1.8mV, n = 15) indicated that the mutations had
no impact on channel selectivity, as was also evidenced by the I–V
curves (Figure 4B). The current reduction was quantiﬁed bymea-
suring the peak current density, which was 563.4± 217.0 pA/pF
(n = 10) for theWT channel, and 132.2± 17.0 pA/pF (n = 14) and
183.6± 15.6 pA/pF (n = 15) for theA124D andV1378Mchannels,
respectively (Figure 5A).
FIGURE 2 | ECG and genotype: Patient 2. (A) 12-lead ECG showing a BrS
type 1 ECG with coved ST-segment elevation in the right precordial leads.
(B) c.4132 G>A resulted in a heterozygous p.V1378M mutation in SCN5A.
The WT and mutant channels had similar gating proper-
ties (Figure 5B; Table 1). There were no statistically signiﬁcant
differences in activation and inactivation parameters (Table 1).
A124D AND V1378M CURRENT DENSITIES WERE RESCUED BY LOW
TEMPERATURE AND DRUG TREATMENTS
tsA201 cells expressing A124D or V1378M mutant channels
were incubated at 25˚C for 24 h or with curcumin, thapsi-
gargin, or mexiletine in an attempt to restore Na+ currents.
The results are shown in Figure 6, Tables 2 and 3. All the
treatments are known to restore trafﬁcking defects induced by
mutations, albeit in different ways. Curcumin and thapsigargin
were diluted in dimethylsulfoxide (DMSO). No differences
were observed between DMSO-treated cells and control cells.
Nevertheless, mutant cells incubated with DMSO alone were
used as controls. The peak current densities of the DMSO-
treated A124D and control cells were 102.4± 16.8 pA/pF (n = 11)
and 132.2± 17.0 pA/pF (n = 14), respectively. The peak cur-
rent densities of the DMSO-treated and untreated V1378M
cells were 163.1± 20.8 pA/pF (n = 8) and 183.6± 15.6 pA/pF
(n = 15), respectively. Curcumin and thapsigargin partially
restored the currents. The peak current density of the A124D
mutant was 200.0± 24.6 pA/pF (n = 16) with curcumin and
214.3± 19.9 pA/pF (n = 7) with thapsigargin. The peak cur-
rent density of the V1378M mutant was 337.6± 31.2 pA/pF
(n = 8) with curcumin and 262.4± 19.9 pA/pF (n = 13) with
thapsigargin.
The peak current density of the V1378M mutant was restored
partially by mexiletine (312.4± 49.1 pA/pF, n = 5) while that of
the A124D mutant was not (105.8± 35.5 pA/pF, n = 5). After
a 24-h incubation at 25˚C, the current densities of the A124D
and V1378M mutants were 338.6± 107.0 pA/pF (n = 6) and
412.5± 88.9 pA/pF (n = 6), respectively. The low temperature
treatment was the most effective in restoring peak current
densities.
To mimic the fever observed in our patient, cells express-
ing mutant channels were incubated for 24-h at 39˚C. The peak
current density was not signiﬁcantly modiﬁed after incubation
neither for A124D (100.2± 20.6 pA/pF, n = 7) nor for V1378M
(144.6± 33.4 pA/pF, n = 7) mutants.
IMMUNOLABELING OF WT AND MUTANT Nav1.5 CHANNELS
Immunocytochemistry was used to clearly understand the impact
of the mutations on the localization of Nav1.5 channel proteins.
FIGURE 3 | Nav1.5 2-D structure. Schematic representation of Nav1.5 structure, arrows point to the localization of the two mutations A124D and V1378M.
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FIGURE 4 | Expression ofWT,A124D, andV1378M Nav1.5 channels in
tsA201 cells. (A) Representative whole-cell current traces ofWT (top),
A124D (middle), and V1378M (bottom) channels. Currents were elicited
using a voltage-clamp protocol where depolarizing pulses were applied for
50ms from −100 to +80mV in 10mV increments. (B) Current–voltage
(I–V ) relationships ofWT (•, n = 10), A124D (•, n = 14), and V1378M (©,
n = 15) channels. All currents were normalized to cellular membrane
capacitance to give the current density (pA/pF).
The channels were taggedwith a Flag epitope to improve the speci-
ﬁcity of the labeling. Patch-clamp experiments were performed to
ensure that the epitope had no effect on the biophysical properties
of theWT andmutant Nav1.5 channels (data not shown). TheWT
channels localized on the membrane (green arrow) and in the ER
(red arrows) whereas the mutant channels (A124D and V1378M)
co-localized on the ER (red arrows; Figure 7A).
After incubating the cells at 25˚C for 24 h, the immunolabeling
was repeated in order to study the impact of the low temperature
treatment. TheWT channels remained localized on the cell mem-
brane (green arrows, upper panel) while the two mutant channels
localized on the cell surface (green arrows) and co-localized on
the ER (red arrows; Figure 7B). The two mutations resulted
in the Nav1.5 mutant channels being retained in the ER while
the incubation at 25˚C almost completely restored the trafﬁcking
defect.
FIGURE 5 | Current densities and gating properties ofWT,A124D, and
V1378M Nav1.5 channels. (A) Histogram summarizing the current
densities of theWT, A124D, and V1378M Nav1.5 channels. Current densities
were signiﬁcantly lower for A124D (132.2± 36.8 pA/pF, n = 14) and V1378M
(183.6± 33.5 pA/pF, n = 15) than forWT (563.4± 217.0 pA/pF, n = 10; ***,
p< 0.001). (B) Voltage dependence of steady-state activation (•) or
inactivation () for theWT (-), A124D (-), and V1378M (- - -) Nav1.5 channels.
Activation curves were generated using a standard Boltzmann distribution
[G(V )/Gmax = 1/(1+ exp(−(V −V 1/2)/k ))] to give the V1/2 and k values listed in
Table 1. Inactivation currents were obtained by applying conditioning
pre-pulses to membrane potentials ranging from a holding potential of
−140 to −10mV for 500ms in 10mV increments and were then measured
using a 4-ms pulse to −30mV at each step (see protocol in inset). The
recorded inactivation values were ﬁtted to a standard Boltzmann equation
[I(V )/Imax = 1/(1+ exp((V −V 1/2)/k ))+C] to give the values listed inTable 1.
DISCUSSION
Our results clearly showed that while the two SCN5A mutations
(A124D and V1378M) caused dramatically reduced current den-
sities, the kinetics and gating properties of the mutant channels
were unaffected. This suggests that these mutant channels could
be made fully functional by restoring their cell surface expression.
In order to identify the cause of the reduction in current density,
cells expressingmutant orWT channels were incubated under sev-
eral conditions. The treatments that we investigated (incubation at
low temperature and with mexiletine, thapsigargin, or curcumin)
are known to restore protein trafﬁcking defects, albeit by differ-
ent molecular mechanisms (Baroudi et al., 2002; Egan et al., 2002;
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Valdivia et al., 2004). The reduction in the current densities of the
mutant channels was caused by their retention in the ER but the
functionality of the channels was restored when they reached the
membrane (Figures 6 and 7).
Alanine at position 124 and valine at position 1378 are
highly conserved in voltage gated Na+ channels. Given this, we
hypothesized thatmutating these two amino acidsmight affect the
protein structure, leading to misfolding, and reticular retention.
Dramatic reductions in Na+ current densities induce signiﬁ-
cant ionic imbalances in cardiomyocytes. As a result, other ionic
currents such as potassium currents (I t0) can become patho-
logically prominent and lead to BrS symptoms (Antzelevitch,
2006).
Interestingly, some WT channels localized in the ER
(Figure 7A). This is in agreement with the results of a study
by Zimmer et al. (2002), who reported that a large proportion
of Nav1.5 Na+ channels localized inside the cell (HEK-293 or
cardiomyocytes), notably to enable adaptive responses.
Whilemexiletine is known to correct Nav1.5 trafﬁcking defects,
the A124D and V1378M mutants did not react in the same way
to a 24-h incubation with 400μM mexiletine. This drug had no
effect on the current density of A124D channels while the current
density of V1378M channels was partially restored. This antiar-
rhythmic drug binds to Nav1.5 channels on a local anesthetic
binding site in the sixth transmembrane segment of the fourth
homologous domain (Weiser et al., 1999). We hypothesized that
when mexiletine binds to V1378M channels in the ER, it acts as a
molecular chaperone and allows the export of the retained chan-
nels. On the other hand, the A124Dmutation in the N-terminus is
Table 1 | Biophysical properties of theWT,A124D, andV1378M Nav1.5
channels.
WT A124D V1378M
Activation n = 10 n = 14 n = 15
V 1/2 (mV) −59.7± 2.2 −56.1± 1.2 −57.1± 1.4
k (mV) −6.8± 0.4 −7.6± 0.2 −7.6± 0.3
Inactivation n = 10 n = 12 n = 15
V 1/2 (mV) −104.7± 2.5 −101.5± 1.4 −103.6± 1.2
k (mV) 4.7± 0.2 4.8± 0.1 4.7± 0.1
V1/2 – Midpoint for activation or inactivation.
k – Slow factor for activation or inactivation.
probably too far from local anesthetic binding site for mexiletine
to be effective, which could explain our results. This suggests that
the ability of mexiletine to rescue trafﬁcking defects may depend
on the location of the mutation. Our ﬁndings further indicated
FIGURE 6 | Maximum current densities ofWT,A124D, andV1378M
Nav1.5 channels in tsA201 cells following various treatments.
Histogram summarizing the current densities of theWT, A124D, and
V1378M mutant channels treated or not with 0.25% DMSO, 25μM
curcumin (4 h), 1μM thapsigargin (2 h), 400μM mexiletine (24 h), at 25˚C
for 24 h or at 39˚C for 24 h. The current densities ofWT, 563.4± 217.0 pA/pF
(n = 10), for A124D, 132.2± 17.0 pA/pF (n = 14) without DMSO,
102.4± 16.8 pA/pF (n = 11) with DMSO, 200.0± 24.6 pA/pF (n = 16) with
curcumin, 214.3± 19.9 pA/pF (n = 7) with thapsigargin, 105.8± 35.5 pA/pF
(n = 5) with mexiletine, and 338.6± 107.0 pA/pF (n = 6) when the cells were
incubated at 25˚C and 100.2± 20.6 pA/pF (n = 7) when the cells were
incubated at 39˚C. Signiﬁcant differences were observed between
DMSO-treated and curcumin- or thapsigargin-treated A124D cells
(*p< 0.05; **p< 0.01) but not between DMSO-treated and control cells. A
signiﬁcant difference was observed between untreated cells grown at 37˚C
and cells grown at 25˚C (#p< 0.05). There was no difference between
untreated and mexiletine-treated or 39˚C-incubated cells. Untreated,
DMSO-, curcumin-, thapsigargin-, mexiletine-, 25˚C-, and 39˚C-treated
V1378M cells had current densities of 183.6± 15.6 pA/pF (n = 15),
163.1± 20.8 pA/pF (n = 8), 337.6± 31.2 pA/pF (n = 8), 262.4± 19.9 pA/pF
(n = 13), 312.4± 49.1 pA/pF (n = 5), 412.5± 88.9 pA/pF (n = 6), and
144.6± 33.4 pA/pF (n = 7) respectively. Signiﬁcant differences were
observed between the DMSO-treated and curcumin- or
thapsigargin-treated V1378M mutant (*p< 0.05; ***p< 0.001) but not
between the untreated and DMSO-treated or 39˚C-incubated cells.
Signiﬁcant differences were observed between the untreated cells and
mexiletine- or 25˚C-treated V1378M mutant (#p< 0.05).
Table 2 | Biophysical properties of the A124D mutant Nav1.5 channel following various treatments.
Untreated DMSO Curcumin Thapsigargin Mexiletine 25˚C
Activation n = 14 n = 11 n = 16 n = 7 n = 5 n = 6
V 1/2 (mV) −56.1± 1.2 −57.2± 1.4 −54.4± 1.2 −55.5± 2.4 −59.1± 2.1 −54.0± 2.1
k (mV) −7.6± 0.21 −7.9± 0.4 −7.7± 0.4 −7.5± 0.6 −7.9± 0.5 −6.7± 0.1
Inactivation n = 12 n = 10 n = 16 n = 7 n = 4 n = 5
V 1/2 (mV) −101.5± 1.4 −105.4± 1.6 −102.5± 1.8 −103.1± 2.1 −107.8± 3.4 −99.4± 3.4
k (mV) 4.8± 0.1 4.8± 0.1 5.0± 0.2 4.7± 0.1 4.5± 0.4 4.5± 0.3
V1/2 – Midpoint for activation or inactivation.
k – Slow factor for activation or inactivation.
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Table 3 | Biophysical properties of theV1378M Nav1.5 mutant channel following various treatments.
Untreated DMSO Curcumin Thapsigargin Mexiletine 25˚C
Activation n = 15 n = 8 n = 8 n = 11 n = 5 n = 6
V 1/2 (mV) −57.1± 1.4 −57.3± 2.1 −61.3± 1.5 −61.2± 1.2 −57.0± 1.3 −56.9± 1.6
k (mV) −7.6± 0.3 −7.2± 0.3 −6.8± 0.4 −6.2± 0.3 −6.8± 0.5 −6.9± 0.8
Inactivation n = 15 n = 8 n = 7 n = 11 n = 4 n = 5
V 1/2 (mV) −103.6± 1.2 −105.8± 2.1 −104.7± 2.3 −105.1± 1.7 −101.3± 0.9 −100.0± 1.3
k (mV) 4.7± 0.1 4.6± 1.3 4.7± 0.1 4.7± 0.2 5.0± 0.2 4.2± 0.1
V1/2 – Midpoint for activation or inactivation.
k – Slow factor for activation or inactivation.
FIGURE 7 | Immunostaining of tsA201 cells expressing the Flag-tagged
WT and mutant Nav1.5 cardiac channels. Images were taken with a
confocal Zeiss microscope equipped with 63× oil immersion objective and
appropriate lasers. Column 1 shows Flag-staining (green), which indicates
Nav1.5 channel staining. Column 2 shows nuclear (blue) and ER (red)
staining. Column 3 shows a merged image of Flag-tagged Nav1.5 staining
(green) and ER staining (red). Column 4 shows a light transmitted image.
The scale bar on the last column is the same for all the line images. For all
the groups (A,B), Nav1.5/WT-Flag is represented on the upper panel,
Nav1.5/A124D-Flag on the middle panel, and Nav1.5/V1378M-Flag on the
lower panel. Red arrows point to ER-localized Flag-Nav1.5 channels, and
green arrows point to membrane-localized Flag-Nav1.5 channels. (A)
Immunocytochemistry performed under normal conditions. (B)
Immunocytochemistry performed after a 24-h incubation at 25˚C.
that mexiletine may be a spatially limited chaperone and, as such,
cannot restore channel functionality if themutation is too far from
its binding site.
Whereas the V1378M mutation was associated with a classic
BrS clinical phenotype, the A124D mutation was associated with
syncope and aBrS type 1ECGwhen the patientwas febrile and that
resolved into a BrS type 3 ECG when the patient was afebrile. In
addition, the patient had a past history of neurally mediated vaso-
vagal syncope. It has recently beenproposed that someBrS patients
have an impaired balance of the autonomic nervous system and
that their syncopal episodes have origins other than ventricular
arrhythmias (Yokokawa et al., 2010). Whether the drugs we used
in in vitro conditions have an inﬂuence on the autonomic ner-
vous system in vivo remains unclear. The index patient exhibited
symptoms when febrile; we therefore tested the effect of higher
temperature mimicking fever. The higher temperatures experi-
enced during fever can activate HSPs (Tulapurkar et al., 2009).
However, incubating transfected cells for 24-h at 39˚C did not sig-
niﬁcantly impact the peak current density (Figure 6). We suggest
that fever might trigger the clinical manifestation of the disease by
yet to uncover mechanism.
Interestingly, our ﬁndings point to potential new therapeutic
approaches. Broad spectrum treatments that target the entire ER
are not the best way to treat trafﬁcking defects since they may
alter more than one cellular function. Speciﬁc therapies using
mexiletine-like drugs that directly target misfolded Na+ channel
proteins may be a better approach. However, a patient-speciﬁc
approach will be required in order to choose the appropriate drug
for a speciﬁc mutation.
LIMITATIONS OF THE STUDY
It is important to note some limitations of this study. Although
drugs are useful research tools to characterize and understand
the pathogenic processes, they cannot be used for clinical appli-
cations because of their potential side effects. First, curcumin
and thapsigargin are two drugs that target the SERCA pump in
the ER membrane. These drugs inhibit lectin chaperones such
as calnexin inducing a partial shutdown of the ER quality con-
trol. Second, high concentrations of mexiletine are needed for
efﬁcient protein trafﬁcking rescue. Under physiological condi-
tions such a concentration of Na+ channel blocker may mask
the beneﬁts of the rescue. The ideal pharmacological strategy
would be to speciﬁcally rescue the trafﬁcking defect of mutated
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channels without affecting normal Na+ channel gating and
permeability.
CONCLUSION
The present study showed that the BrS phenotypes observed in
patients carrying theA124DandV1378Mmutations can explained
by a dramatic reduction in Na+ currents. These mutations might
affect the structure of the channel, causing misfolded proteins and
leading to the retention of these channels in the ER. Immunocyto-
chemical analyses and drug treatments provided evidence for ER
retention. The ability of mexiletine to restore Na+ currents by cor-
recting the trafﬁcking defect might depend on the location of the
mutations. Lastly, correcting trafﬁcking defects may be a valuable
therapeutic approach for treating BrS patients.
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